Michael Abram

Michael Abram is a highly experienced scientific consultant currently working at HilleVax since November 2022. Prior to this role, Michael served as Senior Director and Head of Translational Medicine in R&D at AstraZeneca from December 2018 to October 2022, where responsibilities included leading a team in developing pharmacology strategies and overseeing biomarker assay execution for late-stage clinical studies. Michael has an extensive background in medical affairs and research at Gilead Sciences, where advancements included major HIV product launches, and held positions at the National Cancer Institute and the University of Pittsburgh focusing on HIV drug resistance and virology research. Michael holds a PhD in Molecular Virology and Microbiology from the University of Pittsburgh, an MSc in Medicinal and Pharmaceutical Chemistry from the University of Manitoba, and a BSc (Hons) in Biochemistry from McMaster University.